Subject who showed medically significant adverse events or intolerance with aripiprazole during screening period or as prior experiences.
Subjects with a current DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or personality disorders.
Subjects with diseases of the central nervous system that may impact the assessment of the psychotic symptoms as per investigator's opinion.
Subjects who have been treated with clozapine or long-acting injectable antipsychotic drugs within 3 months prior to the screening.
Subjects who have been treated over maximum maintenance dose (as specified in each label) of oral antipsychotics at screening. (e.g. Aripiprazole>30mg/day, Olanzapine>20mg/day, Risperidone > 6mg/day, Quetiapine > 750mg/day)
Subjects with a significant risk of violent behaviour or a significant risk of committing suicide based on history or investigator's judgment.
Subjects had a history of seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or other medical condition that would expose them to undue risk or interfere with study assessments.
Significant history of drug abuse disorder (including alcohol, as defined in DSM-5 substance use disorder or in the opinion of the investigator) within the last 6 months prior to screening.
Subjects participating another interventional clinical trial within 30 days prior to screening.
Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
Subjects having any other clinically significant finding of the physical examination or laboratory value that make investigator consider that it would be inappropriate to participate in this study.

NCT03376763_exc_T1
Condition
intolerance
NCT03376763_exc_T2
Condition
adverse events
NCT03376763_exc_T3
Qualifier
medically significant
NCT03376763_exc_T4
Drug
aripiprazole
NCT03376763_exc_T5
Temporal
during screening period
NCT03376763_exc_T6
Temporal
as prior experiences
NCT03376763_exc_T7
Scope
adverse events or intolerance
NCT03376763_exc_T8
Scope
during screening period or as prior experiences
NCT03376763_exc_T9
Qualifier
DSM-<U+2163>-TR
NCT03376763_exc_T10
Condition
schizophrenia
NCT03376763_exc_T11
Negation
other than
NCT03376763_exc_T12
Qualifier
SM-<
NCT03376763_exc_T13
Scope
DSM-<U+2163>-TR or 5
NCT03376763_exc_T14
Condition
schizoaffective disorder
NCT03376763_exc_T15
Condition
major depressive disorder
NCT03376763_exc_T16
Condition
bipolar disorder
NCT03376763_exc_T17
Condition
delirium
NCT03376763_exc_T18
Condition
dementia
NCT03376763_exc_T19
Condition
amnesia
NCT03376763_exc_T20
Condition
orderline, isorders.
NCT03376763_exc_T21
Condition
aranoid, isorders.
NCT03376763_exc_T22
Condition
istrionic, isorders.
NCT03376763_exc_T23
Condition
chizotypal, isorders.
NCT03376763_exc_T24
Condition
chizoid, isorders.
NCT03376763_exc_T25
Condition
ntisocial isorders.
NCT03376763_exc_T26
Qualifier
other
NCT03376763_exc_T27
Condition
ognitive isorders.
NCT03376763_exc_T28
Condition
personality disorders
NCT03376763_exc_T29
Scope
cognitive or personality disorders
NCT03376763_exc_T30
Scope
schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia, Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or personality disorders
NCT03376763_exc_T31
Scope
DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia
NCT03376763_exc_T33
Drug
clozapine
NCT03376763_exc_T34
Drug
long-acting injectable antipsychotic drugs
NCT03376763_exc_T35
Temporal
within 3 months prior to the screening
NCT03376763_exc_T36
Reference_point
the screening
NCT03376763_exc_T37
Scope
clozapine or long-acting injectable antipsychotic drugs
NCT03376763_exc_T38
Multiplier
maximum maintenance dose
NCT03376763_exc_T39
Drug
oral antipsychotics
NCT03376763_exc_T40
Temporal
at screening
NCT03376763_exc_T41
Drug
Aripiprazole
NCT03376763_exc_T42
Drug
Olanzapine
NCT03376763_exc_T43
Drug
Risperidone
NCT03376763_exc_T44
Drug
Quetiapine
NCT03376763_exc_T45
Value
> 750mg/day
NCT03376763_exc_T46
Value
> 6mg/day
NCT03376763_exc_T47
Value
>20mg/day
NCT03376763_exc_T48
Value
>30mg/day
NCT03376763_exc_T49
Scope
Aripiprazole>30mg/day, Olanzapine>20mg/day, Risperidone > 6mg/day, Quetiapine > 750mg/day
NCT03376763_exc_T50
Scope
maximum maintenance dose (as specified in each label) of oral antipsychotics
NCT03376763_exc_T51
Observation
violent behaviour
NCT03376763_exc_T52
Condition
committing suicide
NCT03376763_exc_T53
Mood
significant risk
NCT03376763_exc_T54
Mood
significant risk
NCT03376763_exc_T55
Condition
seizures
NCT03376763_exc_T56
Condition
neuroleptic malignant syndrome
NCT03376763_exc_T57
Qualifier
clinically significant
NCT03376763_exc_T58
Condition
tardive dyskinesia
NCT03376763_exc_T60
Observation
history
NCT03376763_exc_T61
Scope
seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia